

Tools of Recombinant DNA Technology

Koushik Ganguli
Department of Botany
Visva-bharati (A Central University)
Santiniketan, Bolpur, India
Itzmekoushik.personal@gmail.com

Dr. Anjalika Roy
Department of Botany
Visva-bharati (A Central University)
Santiniketan, Bolpur, India
anjalika.roy@visva-bharati.ac.in

ABSTRACT

In the Rat-race of development, technology is the main weapon. In the field of biology also, technology is developing very rapidly. Application of recombinant DNA technology is a major weapon created in the field of biology resulted a new oppurtunities in the field of agriculture, medicine and bioremediation. The new genes are cloned and expressed to produce recombinant drugs which play key role against human lethal diseases. Human genome project is a another breakthrough. Gene knockout helps in gene therapy. DNA profiling helps in solving criminal cases etc.

I. INTRODUCTION

The traditional approach of overcoming agricultural, medical and environmental problems through conventional techniques are now replaced by Recombinant DNA Technology which put forward a new revolution in modern era like edible vaccine or new mutant mice for research purposes. Making a new combination of DNA by manipulating through biotechnological and biochemical means is known as recombinant DNA technology. It may be insertion(s) or/and deletion(s) of DNA. To insert a gene of interest first the gene should be identified and then isolated. This process of recombination also known as genetic engineering and the product is called recombinant DNA. In 1973 Paul berg developed first recombinant DNA molecule by combining genomic content of two viruses, SV40 and lambda phage. Later, in 1973, Boyer, Chang, Cohen and Helling produce a recombinant plasmid DNA molecule[1].




Figure 1: Functional aspects of Recombinant DNA Technology

II. GENE CLONING

The recombinant DNA technology was started with Gene cloning. The techniques are done to assemble DNAs and to replicate in a host body are called gene cloning. In this method one DNA copied into several copies. The process of making several identical DNA molecules from a single ancestral DNA molecule is known as DNA cloning. DNA cloning's key component is the selective amplifying of the desired DNA fragments, which results in a significant rise in the number of copies of the chosen DNA sequences. In actuality, a DNA polymerase operating on one or more varieties of template DNA molecules catalyses several rounds of DNA replication. Cell-based and cell-free DNA cloning are essentially two distinct DNA cloning methods [2]. If the cloning is done *in vivo* or inside a cell, then it is called **cell based cloning**. It is done inside the bacteria because, bacterial cell proliferation rate is high. For cell based cloning, the vector should contain Multiple Cloning Sites (MCSs) and any one or more marker gene for screening. Later, another technique is invented by Kary Mullis called Polymerase Chain Reaction or PCR which is **cell free gene cloning** technique. In PCR, all the important raw material (e.g., Gene of Interest, dNTPs, Primer, Taq Polymerase, Mg^{2+} and buffer) has to provide into a PCR tube and placed in the PCR machine or Tharmocycler [3]. This method is only for increasing copy number of a gene.

Therefore gene cloning is mainly used to multiply a segment of DNA.




Figure 2: Method of cell-based Gene Cloning

III. GENE EXPRESSION

The process through which a gene's information is used to produce either RNA molecules that code for proteins or non-coding RNA molecules with other roles, is known as gene expression. When and where RNA molecules and proteins are produced, as well as their quantity, are controlled by gene expression, which also serves as a "on/off switch" and a "volume control". Gene expression is tightly controlled and significantly changes depending on the environment. Many genes produce RNA and proteins that control the expression of other genes. Gene expression is very much similar to cell based gene cloning. This technique is done to synthesize protein by expressing a particular gene in host body in laboratory condition. E.g., Insulin production.

Gene expression system categorised on the basis of the host nature: Prokaryotic Expression system and Eukaryotic expression system. Prokaryotic expression system, particularly *E. Coli*, is widely used system [3]. Now a days, it is very popular technique to produce vaccine, Growth hormones, Antibodies, Vectors, Recombinant protein, Anticancer drugs [4].




Figure 3: Method of gene expression

IV. GENE KNOCK OUT

Gene knock out is a method to lost a particular activity by removing the complete gene. The gene knock out technique processes are TK/Neo^R cassette also called replacement vector or CRE/LoxP recombination. TK and Neo^R both are screening marker gene. TK or Thimidine kinase is shows sensitivity to glasciclovir and Neo^R is resistant to Neomycine [3].

Cre-Lox recombination is a site-specific recombinase technology, used to carry out deletions, insertions, translocations and inversions at specific sites in the DNA. It allows the DNA modification to be targeted to a specific cell type or be triggered by a specific external stimulus. It is implemented both in eukaryotic and prokaryotic systems. The system consists of a single enzyme, Cre recombinase, that recombines a pair of short target sequences called the Lox sequences. This system can be implemented without inserting any extra supporting proteins or sequences. The Cre enzyme and the original Lox site called the LoxP sequence which is derived from bacteriophage P1. Placing Lox sequences appropriately allows genes to be activated, repressed, or exchanged for other genes. At a DNA level many types of manipulations can be carried out. The activity of the Cre enzyme can be controlled so that it is expressed in a particular cell type or triggered by an external stimulus like a chemical signal or a heat shock. These targeted DNA changes are useful in cell lineage tracing and when mutants are lethal if expressed globally. The Cre-Lox system is very similar in action and usage to the FLP-FRT recombination system [5].

It is used to study function of gene. Sometimes used for gene therapy and development of recombinant organism.

V. GENOME MAPPING

Gene locations and the distances between them on a chromosome are found and recorded using genome mapping. A crucial foundation for the Human Genome Project was laid via genome mapping. mapping gives an estimation of the (physical) distance between specific known DNA sequences on a chromosome. The distance between these known DNA sequences on a chromosome is expressed as the number of base pairs between them. There are several different techniques used for physical mapping. These include:

- i. Restriction mapping (fingerprint mapping and optical mapping)
- ii. Fluorescent in situ hybridisation (FISH) mapping
- iii. Sequence tagged site (STS) mapping.

VI. DNA PROFILLING

Any DNA-based method that identifies a specific individual's or group's DNA within an organism community is referred to as DNA fingerprinting or DNA profiling. A DNA sample can identity or the degree to which different DNA samples are connected to one another can be ascertained by using the DNA fingerprints. DNA profiling play a centre stage role in Forensic Science and criminal investigation. In the year of 1984, a British Geneticist named Dr. Alec Jeffreys developed a technique to individualize two different people by their DNA. Jeffery's technique was basically depending on VNTR (Variable Number of Tandem Repeats). In this case he uses some non-coding (introns) regions of DNA which was highly variable between two people. Jeffery analysed some repetitive sequence present over DNA which is highly polymorphic.

Later other DNA profiling techniques like RFLP, RAPD, STR, SNP etc. are introduced. But these all techniques are depending on VNTR. DNA profiling has a potential application like in kidnapping cases, identifying of missing person, Disaster Victim Identification, Biological parent identification, Criminal identification etc. DNA profiling can't distinguish between monozygotic twins as they share same genomic data of both parents.





Figure 4: DNA profiling procedure

VII. cDNA LIBRARY

A messenger ribonucleic acid (mRNA) that has been entirely translated and solely includes the expressed genes of an organism produces complementary DNA (cDNA). The term "cDNA clones" refers to copies of such mRNAs in DNA. A cDNA library is a collection of cloned cDNA fragments introduced into various host cells, each of which



makes up a small piece of the organism's transcriptome. As opposed to DNA, mRNA is used to create cDNA libraries. To translate DNA information into protein, messenger RNA transports the information from ribosomes. Reverse transcriptase, an enzyme that creates a DNA copy of an mRNA, is applied to these mRNA molecules to produce a cDNA library (i.e., cDNA). An untranscribed area is included in a genomic library, whereas a cDNA library only contains a sample of the transcribed genes.

Figure 5: Method of cDNA library making

VIII. TRANSGENIC ORGANISM

Any organism whose genetic makeup changed using genetic engineering methods is a genetically modified organism (GMO) or transgenic organism. Animals, plants, microbes, and many other types of species have undergone genetic modification (GM). Genes have been moved between members of the same species, between species (resulting in transgenic creatures), and even between kingdoms. Endogenous genes can be strengthened, changed, or taken out, as well as new genes. The creation of GMOs has become significantly easier thanks to recent developments in genome editing technologies, particularly CRISPR/Cas system.

The DNA must be transported across the cell membrane without damaging the cell in order to create a transgenic cell. In some circumstances, introducing DNA to the medium and momentarily expanding the membrane's porosity, such as by electroporation, might result in the transfer of naked DNA into the cell. Using a specialised needle and bigger cells, bare DNA may be microinjected into a cell. In other procedures, DNA is transported across the membrane using vectors. Vesicles consisting of lipids or other polymers that enclose DNA, different types of particles with DNA on their surfaces, infectious viruses and bacteria, which naturally transfer their own DNA into a host cell, and modified viruses and bacteria which can transport any DNA molecule of interest are all examples of vectors for transformation or transfection. The foreign DNA must be absorbed into the host's chromosomes when the goal of an experiment is to create a stable (i.e. heritable) transgenic eukaryote. For this, the foreign DNA has to enter the host's nucleus and unite with a host chromatid. In certain animals, the foreign DNA is inserted randomly into a chromatid, likely wherever strand breaks and non-homologous end joins. By placing DNA that is identical to the host's DNA at that locus on each side of the foreign DNA, it is possible for other species to direct the foreign DNA to a specific locus. Homologous recombination is then used to insert the foreign DNA into the host's chromosomes. A stable (i.e. heritable) transgenic eukaryote must be created when the goal of an experiment is to develop one. For successful transgenic, the foreign DNA has to penetrate the host cell's nucleus and unite with a chromatid. In certain animals, the foreign DNA is randomly inserted into a chromatid, likely wherever strand breaking and NHEJ (Non-Homologous End Joining) happen to take place. When foreign DNA is flanked by DNA that is identical to the host's DNA at a certain locus, the foreign DNA can be directed to a specific locus in other species. After then, homologous recombination occurs to integrate the foreign DNA into the host's chromosomes.




Figure 6: Transgenic organism development

IX. GENE THERAPY

Gene therapy is a branch of medicine that focuses on altering a cell's genetic makeup to have a therapeutic impact or to treat a disease by replacing or repairing damaged genetic material [6]. French Anderson, the inventor of gene therapy, used gene transfer for the first time therapeutically and directly inserted human DNA into the nuclear genome in a study that began in September 1990 [7].

Gene therapy is differentiated into two types depending on treated cell type: Somatic gene therapy, when genetic therapeutic treatment is done on any body cell that doesn't produce gametes and germline gene therapy, when genetic therapeutic treatment is done on gamete mother cells. On the basis of therapeutic methods, it may differentiate into three categories; Gene augmentation therapy, Gene inhibition therapy, Killing of specific cells. Gene augmentation therapy is used when a loss of function mutation caused into the cell thus the protein production obstructed. This treatment replenishes the cell's DNA with a functioning copy of the missing gene. The new gene creates a functional protein in high enough quantities to replace the lost protein. Gene inhibition therapy is used to inhibit a gene mutated as gain of function and/or affecting any other metabolic reactions. Killing of specific cells as the name suggests it is a killing technique. It is preferred for conditions like cancer that may be treatable by destroying specific cell types.

X. APPLICATIONS OF RECOMBINANT DNA TECHNOLOGY

Food and agriculture: Major advancements in recombinant DNA technology have made it feasible to produce unique enzymes that are appropriate for certain food processing settings. Due to their specialised functions and uses in the food industry, several significant enzymes, such as lipases and amylases, are accessible for the specific manufactures. Another significant accomplishment made possible with the use of recombinant DNA technology is the generation of microbial strains. Numerous microbial strains have been created that can manufacture enzymes, specifically proteases, by targeted engineering. Some fungal strains have undergone modifications to reduce their capacity to produce hazardous compounds [8]. DspB, a protein created from T7, can hydrolyze the exopolysaccharides of *Staphylococcus* and *E. coli*. The bacterial population declines as a result of DspB's activity [9]. The idea of oral vaccination using edible plants has gained popularity with the development of HBV vaccine production in plants. Plants have been exploited to manufacture several therapeutic protein products, like casein and lysozyme for enhancing health of children and polymers of protein for tissue replacement and surgery [10]. Additionally, tobacco plants can be genetically modified to make human collagen.

Health and diseases: RDT has a wide spectrum of use in health and disease treatment.

1. Gene therapy Advanced medical technology with therapeutic potential includes gene therapy. The first successful study of gene therapy for the treatment of a genetic condition offered a more reliable path toward healing the most lethal hereditary disorders [11,12]. A focused approach with the potential to be therapeutically beneficial is gene transfer to a few cells at anatomically distinct places. For severe autosomal recessive dystrophies including congenital blindness and Leber congenital amaurosis, it shown amazing outcomes (LCA) [13]. Gene therapy for the treatment of cardiovascular disorders is a significant medical research method. Gene therapy will open up new possibilities for therapeutic angiogenesis, myocardial protection, regeneration, and repair, prevention of restenosis after angioplasty, avoidance of bypass graft failure, and risk factor management in the field of cardiovascular medicine. Wiskott-Aldrich Syndrome is brought on by a mutation in the gene that codes for WASP, a protein that controls the cytoskeleton (inherited immunodeficiency). When matched donors are not available for stem cell transplantation, the condition is treated by injecting autologous HSPCs that have undergone *ex vivo* gene therapy [14]. One of the main oncogenic pathways in many malignancies is Wnt signalling. An appealing therapeutic strategy for treating cancer is to target the Wnt system, and LGK974 potentially blocks Wnt signalling, has good effectiveness in rodent tumour models. High levels of LGK974 response are observed in head and neck cancer cell lines with loss-of-function mutations in the Notch signalling system [15]. The CRISPR/Cas9 technology has given gene therapy a second chance to shed its bad reputation and establish itself as an effective therapeutic approach. A new age of CRISPR gene therapy is now possible because to the recent introduction of CRISPR technology in clinical trials. However, before contemplating its application in patient care, a number of technological and ethical issues need to be resolved.

2. Antibiotic and vaccine production Antibiotic production is a huge contribution of biotechnology for human health. Along with bacteria and fungi, plant systems have been recently used for the expression and development of different antibodies and their derivatives. Chimeric secretory IgA/G, also known as CaroRx, can be produced by transgenic tobacco plants. This antibody may identify the oral pathogen *Streptococcus* mutants,

which causes tooth decay. Antigen carcinoembryonic, which is still regarded as an effectually described marker in malignancies of the epithelia, may be functionally recognised by the monoclonal antibody T84.66. [16,17] Recombinant vaccines are more effective and specific than traditional vaccinations. Nasal transfer, which is also a quick and effective strategy for preserving protection against mucosal diseases, is a fearless and painless method of transferring adenovirus vectors expressing pathogen antigens. In order to produce an anti-influenza state, a transgene must be expressed in the airway [18] which serves as a pharmacological vaccination.

Solving environmental issues: Numerous environmental problems can be solved through genetic engineering like the release of genetically modified bacteria for bioremediation in the field, such as the HK44 strain of *Pseudomonas fluorescens*. The altered strain has a transposon-based bioluminescence-producing lux gene linked within a promoter, a naphthalene catabolic plasmid called pUTK21, and increased naphthalene breakdown as a consequence [19].

1. Phytoremediation For the detection and absorption of pollutants in drinking water and other samples, genetic engineering has been widely applied. For instance, the insertion of the AtPHR1 gene into the garden plants like *Verbena sp.*, *Torenia sp.*, and *Petunia sp.* altered their capacity to absorb Pi [20]. The improved Pi absorption capacity of the AtPHR1 transgenic plants may make efficient phytoremediation in contaminated aquatic settings. In binary vector pBinPLUS, which has an improved cauliflower mosaic virus 35S promoter, a segment of the AtPHR1 gene was introduced [21]. *Agrobacterium tumefaciens* was utilised to convert *Petunia* and *Verbena* using this plasmid, designated pSPB1898. Recombinant DNA technology has demonstrated its efficacy in eliminating soil pollutants such as arsenic, which is regarded as a major one [22]. *Arabidopsis* expressed PvACR3, a crucial arsenite [As(III)] antiporter that exhibited increased arsenic tolerance. Unlike wild-type seeds, which often die in the presence of greater than usual concentrations of arsenate [As(V)], seeds of plants genetically altered with PvACR3 may germinate and flourish under these conditions. As reductase is an enzyme found in *A. thaliana* that reduces arsenic (As). Phytochelatins limit the migration of arsenic in phloem companion cells and root cells. The transporters that take up cadmium (Cd) and retain it are OsNramp5 and OsHMA3 [23]. Brassino-steroid (BR) has a role in controlling physiological and developmental processes in plants. Its action is initiated by activating a cascade of phosphorylation or dephosphorylation [24].

2. Energy production: The creation of hydrogen, an environmentally acceptable energy source, is mediated by a number of microorganisms, including cyanobacteria. Because these enzymes are crucial for the creation of the product, their right use is essential to maintaining the specific manufacturing. However, cutting-edge methods such as genetic engineering, nutrition and growth environment modification, combination culture, metabolic engineering, and cell-free technologies have produced promising results for boosting the hydrogen generation in cyanobacteria and other biofuels. In the fields of bioelectronics, bioremediation, and renewable energy, *Geobacter sulfurreducens*'s conductive biofilms have potential as sources [24-26]. The *G. sulfurreducens* biofilm became more active when PilZ genes, which encode proteins, were deleted from the genome. The strain with the gene GSU1240 deleted is designated by the designation CL-1ln. Exopolysaccharide and pili production were both improved along with biofilm creation. When cultivated with electrode, the biofilms of the electron acceptor CL-1 were six times more conductive than those of the wild-type. Due to decreased charge transfer resistance at the surface of the biofilm anode and lower formal potential, the high fold conductivity reduced the potential losses in microbial fuel cells thus increases potential energy [27].

XI. FUTURE ASPECTS OF RECOMBINANT DNA TECHNOLOGY

Prokaryotes are used to produce enzymes, however there are a few drawbacks, including posttranslational changes, activation of cell stress responses, instability of proteolytic activity, limited solubility, and resistance to the expression of new genes. Recombinant DNA technology is now undergoing rapid growth, which has drastically altered study areas and offered new, exciting avenues for investigating biosynthetic processes through genetic modification [28]. Gene therapy using recombinant DNA technology is a method for both preventing and treating acquired genetic abnormalities. The creation of DNA vaccines is a novel method for preventing many illnesses. The DNA supplied during this procedure contains genes that produce harmful proteins. In clinical trials, human gene therapy is mostly used to treat cancer. High transfection effectiveness in relation to creating gene delivery systems has been the major focus of research. It is still matter of rigorous research whether transfection might be used for cancer gene therapy with minimum side effects, such as in

cases of brain, breast, lung, and prostate cancer. Gene therapy is also being considered for renal transplantation, Gaucher disease, haemophilia, Alport syndrome, renal fibrosis, and a few other conditions [29].

It has developed ways in recent years for medicinal applications such the treatment of cancer, hereditary illnesses, diabetes, and numerous other ailments, particularly virus and fungus resistance. Recombinant DNA technology has been highly acknowledged for its contribution to environmental cleanup (phytoremediation and microbial remediation) and improved plant resistance to many harmful causes (drought, pests, and salt). It made substantial advancements in plants, microbes, and humans. The obstacles in generating end products at the gene level occasionally present severe challenges that must be resolved for the benefit of the future of recombinant DNA technology. There are significant problems in the pharmaceutical industry, producing high-quality end products since the human body may reject the alteration made in a gene particularly. The failure of Bt brinjal is challenging for us. This signifies that growing a recombinant product is not necessarily a good thing because a variety of circumstances might work against its success. However Recombinant DNA technology is assisting in treating a number of diseases that cannot be treated under normal circumstances, also helping in solving environmental issues and agricultural self-sufficiency.

REFERENCES

1. Halford, N. (2006). Plant biotechnology crops. Chichester: John Wiley & Sons.
2. Kumar, P., & Mina, U. (2019). Life sciences: Fundamentals and practice II. New Delhi: Pathfinder Publication.
3. Brown, T. A. (2020). *Gene cloning and DNA analysis: an introduction*. John Wiley & Sons.
4. Khan, s., ullah, m. W., siddique, r., nabi, g., manan, s., yousaf, m., & hou, h. (2016). Role of recombinant dna technology to improve life. *International journal of genomics*, 2016, 2405954. <https://doi.org/10.1155/2016/2405954>
5. Turan, S., Galla, M., Ernst, E., Qiao, J., Voelkel, C., Schiedlmeier, B., ... & Bode, J. (2011). Recombinase-mediated cassette exchange (RMCE): traditional concepts and current challenges. *Journal of molecular biology*, 407(2), 193-221.
6. Kaji, E. H., & Leiden, J. M. (2001). Gene and stem cell therapies. *Jama*, 285(5), 545-550.
7. Gene Therapy Clinical Trials Worldwide Database Archived 31 July 2020 at the Wayback Machine. *The Journal of Gene Medicine*. Wiley (June 2016)
8. Olempska-Beer, Z. S., Merker, R. I., Ditto, M. D., & DiNovi, M. J. (2006). Food-processing enzymes from recombinant microorganisms—a review. *Regulatory toxicology and Pharmacology*, 45(2), 144-158.
9. Torres, C. E., Lenon, G., Craperi, D., Wilting, R., & Blanco, Á. (2011). Enzymatic treatment for preventing biofilm formation in the paper industry. *Applied Microbiology and Biotechnology*, 92(1), 95-103.
10. Ma, J. K., Drake, P. M., & Christou, P. (2003). The production of recombinant pharmaceutical proteins in plants. *Nature reviews genetics*, 4(10), 794-805.
11. Haccin-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J. P., ... & Cavazzana-Calvo, M. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. *New england journal of medicine*, 346(16), 1185-1193.
12. Haccin-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J. P., ... & Cavazzana-Calvo, M. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. *New england journal of medicine*, 346(16), 1185-1193.
13. Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., ... & Grez, M. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVII, PRDM16 or SETBP1. *Nature medicine*, 12(4), 401-409.
14. Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., ... & Naldini, L. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. *Science*, 341(6148), 1233151.
15. Liu, J., Pan, S., Hsieh, M. H., Ng, N., Sun, F., Wang, T., ... & Harris, J. L. (2013). Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. *Proceedings of the National Academy of Sciences*, 110(50), 20224-20229.
16. Stöger, E., Vaquero, C., Torres, E., Sack, M., Nicholson, L., Drossard, J., ... & Fischer, R. (2000). Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. *Plant molecular biology*, 42(4), 583-590.
17. Vaquero, C., Sack, M., Schuster, F., Finner, R., Drossard, J., Schumann, D., ... & Fischer, R. (2002). A carcinoembryonic antigen-specific diabody produced in tobacco. *The FASEB journal*, 16(3), 408-410.
18. Zhang, J., Tarbet, E. B., Toro, H., & Tang, D. C. C. (2011). Adenovirus-vectored drug–vaccine duo as a potential driver for conferring mass protection against infectious diseases. *Expert review of vaccines*, 10(11), 1539-1552.
19. King, J. M. H., DiGrazia, P. M., Applegate, B., Burlage, R., Sanseverino, J., Dunbar, P., ... & Saylor, G. A. (1990). Rapid, sensitive bioluminescent reporter technology for naphthalene exposure and biodegradation. *Science*, 249(4970), 778-781.
20. Matsui, K., Togami, J., Mason, J. G., Chandler, S. F., & Tanaka, Y. (2013). Enhancement of phosphate absorption by garden plants by genetic engineering: a new tool for phytoremediation. *BioMed Research International*, 2013.
21. Horsch, R. B., Fry, J. E., Hoffmann, N. L., Wallroth, M., Eichholtz, D., Rogers, S. G., & Fraley, R. T. (1985). A simple and general method for transferring genes into plants. *science*, 227(4691), 1229-1231.
22. Tamura, M., Togami, J., Ishiguro, K., Nakamura, N., Katsumoto, Y., Suzuki, K., ... & Tanaka, Y. (2003). Regeneration of transformed verbena (*Verbena × hybrida*) by *Agrobacterium tumefaciens*. *Plant Cell Reports*, 21(5), 459-466.
23. Clemens, S., & Ma, J. F. (2016). Toxic heavy metal and metalloids accumulation in crop plants and foods. *Annu Rev Plant Biol*, 67(1), 489-512. Kim, E. J., Youn, J. H., Park, C. H., Kim, T. W., Guan, S., Xu, S., ... & Kim, T. W. (2016). Oligomerization between BSU1 family members potentiates brassinosteroid signaling in *Arabidopsis*. *Molecular plant*, 9(1), 178-181.

24. Kim, E. J., Youn, J. H., Park, C. H., Kim, T. W., Guan, S., Xu, S., ... & Kim, T. W. (2016). Oligomerization between BSU1 family members potentiates brassinosteroid signaling in Arabidopsis. *Molecular plant*, 9(1), 178-181.
25. Ullah, M. W., Ul-Islam, M., Khan, S., Kim, Y., & Park, J. K. (2015). Innovative production of bio-cellulose using a cell-free system derived from a single cell line. *Carbohydrate Polymers*, 132, 286-294.
26. Ullah, M. W., Khattak, W. A., Ul-Islam, M., Khan, S., & Park, J. K. (2016). Metabolic engineering of synthetic cell-free systems: strategies and applications. *Biochemical Engineering Journal*, 105, 391-405.
27. Leang, C., Malvankar, N. S., Franks, A. E., Nevin, K. P., & Lovley, D. R. (2013). Engineering *Geobacter sulfurreducens* to produce a highly cohesive conductive matrix with enhanced capacity for current production. *Energy & Environmental Science*, 6(6), 1901-1908.
28. Ferrer-Miralles, N., Domingo-Espín, J., Corchero, J. L., Vázquez, E., & Villaverde, A. (2009). Microbial factories for recombinant pharmaceuticals. *Microbial cell factories*, 8(1), 1-8.
29. Misra, A. (Ed.). (2010). *Challenges in delivery of therapeutic genomics and proteomics*. Elsevier.